Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 4/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21189189 | 0.90 | MEN1 (0.38) | BACE1BACE2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21189427 | 0.89 | NPC1 (0.39) | PTGESP2RX7GRM4NPC1RAB9A | |
| SCHEMBL19973466 | 0.89 | NPC1 (0.44) | P2RX7GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21189264 | 0.89 | NPC1 (0.44) | P2RX7GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21189330 | 0.89 | NPC1 (0.44) | P2RX7GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21189272 | 0.88 | GRM4 (0.36) | P2RX7GRM4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21189250 | 0.88 | GRM4 (0.36) | PTGESP2RX7GRM4NPC1RAB9A | |
| SCHEMBL21189337 | 0.86 | P2RX7 (0.39) | PTGESP2RX7GRM4 | |
| SCHEMBL21189252 | 0.86 | TRPV1 (0.36) | PTGESP2RX7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21189289 | 0.85 | NPC1 (0.46) | P2RX7GRM4NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-05-11 | — | — | US | disclosed |
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225593-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | CBX8, HAVCR2, HCCS | PTGES 4518/4885P2RX7 676/4885GRM4 3439/4885 |
| US-11001564-B2 | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | CBX8, HAVCR2, HCCS | PTGES 4518/4885P2RX7 676/4885GRM4 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.